Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 3 institutions in 1 country.
Rosalyn C ZimmermannDepartment of Cancer Biology, The Kansas University Medical Center, Kansas City, KS, United States of America.ORCID 0000-0001-8611-2545
Mihaela E SardiuStowers Institute for Medical Research, Kansas City, Missouri, United States of America.ORCID 0000-0002-3987-7569
Christa A MantonDepartment of Cancer Biology, The Kansas University Medical Center, Kansas City, KS, United States of America.ORCID 0000-0003-1356-828X
Md Sayem MiahStowers Institute for Medical Research, Kansas City, Missouri, United States of America.ORCID 0000-0002-5901-5181
Charles A S BanksStowers Institute for Medical Research, Kansas City, Missouri, United States of America.ORCID 0000-0002-0404-2940
Mark K AdamsStowers Institute for Medical Research, Kansas City, Missouri, United States of America.ORCID 0000-0002-1078-9514
Devin C KoestlerDepartment of Biostatistics and Data Science, The Kansas University Medical Center, Kansas City, KS, United States of America.ORCID 0000-0002-0598-0146
Douglas R HurstPathology Department, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Mick D EdmondsDepartment of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.ORCID 0000-0001-5049-7180
Michael P WashburnDepartment of Cancer Biology, The Kansas University Medical Center, Kansas City, KS, United States of America.ORCID 0000-0001-7568-2585
Danny R WelchDepartment of Cancer Biology, The Kansas University Medical Center, Kansas City, KS, United States of America.ORCID 0000-0002-1951-4947
Stowers Institute for Medical Research · USUniversity Medical Center · USUniversity of Alabama at Birmingham · US
Funding
Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SUSAN J. BROWN · 2012 to 2026
$63.0M
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Kalyani Pyaram, Steven Allan Soper · 2019 to 2026
$21.5M
Inhibitor Reprogramming of a Human Histone Deacetylase Protein Interaction NetworkR01GM112639 · NIGMS · STOWERS INSTITUTE FOR MEDICAL RESEARCH · PI FLORENS, LAURENCE ALEXANDRA · 2016 to 2020
$1.6M
KISS1: Defining Mechanisms for Antimetastatic TherapyR01CA134981 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI WELCH, DANNY R. · 2009 to 2014
$1.5M
Characterization of the SIN3A and SIN3B HDAC complexesF32GM122215 · NIGMS · STOWERS INSTITUTE FOR MEDICAL RESEARCH · PI ADAMS, MARK K · 2017 to 2018
Breast Cancer Metastasis Suppressor 1 (BRMS1) expression is associated with longer patient survival in multiple cancer types. Understanding BRMS1 functionality will provide insights into both mechanism of action and will enhance potential therapeutic development. In this study, we confirmed that the C-terminus of BRMS1 is critical for metastasis suppression and hypothesized that critical protein interactions in this region would explain its function. Phosphorylation status at S237 regulates BRMS1 protein interactions related to a variety of biological processes, phenotypes [cell cycle (e.g., CDKN2A), DNA repair (e.g., BRCA1)], and metastasis [(e.g., TCF2 and POLE2)]. Presence of S237 also directly decreased MDA-MB-231 breast carcinoma migration in vitro and metastases in vivo. The results add significantly to our understanding of how BRMS1 interactions with Sin3/HDAC complexes regulate metastasis and expand insights into BRMS1's molecular role, as they demonstrate BRMS1 C-terminus involvement in distinct protein-protein interactions.
Indexed as
Breast NeoplasmsNeoplasm MetastasisRepressor ProteinsAnimalsCell Line, TumorCell MovementFemaleHumansMiceNeoplasm ProteinsPhosphorylationProtein BindingProtein Interaction MapsSin3 Histone Deacetylase and Corepressor ComplexBRMS1 protein, humanNeoplasm ProteinsRepressor ProteinsSin3 Histone Deacetylase and Corepressor Complex
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Perturbation of BRMS1 interactome reveals pathways that impact metastasis. · full record | OpenQuestion